MCID: THR001
MIFTS: 53

Thrombocytopenia Due to Platelet Alloimmunization

Categories: Rare diseases, Immune diseases, Blood diseases, Genetic diseases

Aliases & Classifications for Thrombocytopenia Due to Platelet Alloimmunization

MalaCards integrated aliases for Thrombocytopenia Due to Platelet Alloimmunization:

Name: Thrombocytopenia Due to Platelet Alloimmunization 12 14 69
Immune Thrombocytopenia 12 72 49 24 36 59
Autoimmune Thrombocytopenia 24 28 51 69
Immune Thrombocytopenic Purpura 24 69
Thrombocytopenia Due to Immune Destruction 12
Idiopathic Thrombocytopenic Purpura 24
Autoimmune Thrombocytopenic Purpura 24
Auto-Immune Thrombocytopenia 12
Werlhof Disease 24
Itp 24

Classifications:



External Ids:

Disease Ontology 12 DOID:1587
NCIt 46 C3991
SNOMED-CT 64 2897005
KEGG 36 H01240

Summaries for Thrombocytopenia Due to Platelet Alloimmunization

PubMed Health : 59
About immune thrombocytopenia: Immune thrombocytopenia (THROM-bo-si-toe-PE-ne-ah), or ITP, is a bleeding disorder. In ITP, the blood doesn't clot as it should. This is due to a low number of blood cell fragments called platelets (PLATE-lets) or thrombocytes (THROM-bo-sites).Platelets are made in your bone marrow along with other kinds of blood cells. They stick together (clot) to seal small cuts or breaks on blood vessel walls and stop bleeding.

MalaCards based summary : Thrombocytopenia Due to Platelet Alloimmunization, also known as immune thrombocytopenia, is related to thrombocytopenic purpura, autoimmune and thrombocytopenia. An important gene associated with Thrombocytopenia Due to Platelet Alloimmunization is FCGR2C (Fc Fragment Of IgG Receptor IIc (Gene/Pseudogene)), and among its related pathways/superpathways are Phagosome and Osteoclast differentiation. The drugs Dexamethasone and Amodiaquine have been mentioned in the context of this disorder. Affiliated tissues include bone marrow, bone and testes, and related phenotypes are cellular and hematopoietic system

Genetics Home Reference : 24 Immune thrombocytopenia is a disorder characterized by a blood abnormality called thrombocytopenia, which is a shortage of blood cell fragments called platelets that are needed for normal blood clotting.

Wikipedia : 72 Immune thrombocytopenia (ITP) is a type of thrombocytopenic purpura defined as isolated low platelet... more...

Related Diseases for Thrombocytopenia Due to Platelet Alloimmunization

Diseases in the Thrombocytopenia family:

Thrombocytopenia 2 Thrombocytopenia 3
Thrombocytopenia 1 Thrombocytopenia 4
Thrombocytopenia 5 Thrombocytopenia 6
Acquired Thrombocytopenia Thrombocytopenia Due to Platelet Alloimmunization
Primary Thrombocytopenia

Diseases related to Thrombocytopenia Due to Platelet Alloimmunization via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 50)
# Related Disease Score Top Affiliating Genes
1 thrombocytopenic purpura, autoimmune 31.0 FCGR2C ITGA2B MPL SELP THPO
2 thrombocytopenia 28.5 ITGA2 ITGA2B MPL MYH9 THPO
3 autoimmune hemolytic anemia-autoimmune thrombocytopenia-primary immunodeficiency syndrome 12.0
4 evans' syndrome 11.2
5 thrombocytopenia 3 10.2 MPL THPO
6 thrombocythemia 1 10.2 MPL THPO
7 dyskeratosis congenita, autosomal dominant 6 10.2 MPL THPO
8 amegakaryocytic thrombocytopenia, congenital 10.2 MPL THPO
9 autosomal dominant macrothrombocytopenia 10.2 ITGA2B MYH9
10 carotid artery thrombosis 10.2 ITGA2B SELP
11 fetal and neonatal alloimmune thrombocytopenia 10.1 ITGA2 ITGA2B
12 leukocyte adhesion deficiency, type iii 10.1 ITGA2B SELP
13 intermediate coronary syndrome 10.1 ITGA2B SELP
14 thrombocytopenia-absent radius syndrome 10.0 MPL THPO
15 hemorrhagic disease 10.0 ITGA2B MPL THPO
16 pancytopenia 9.9 MPL THPO
17 splenic disease 9.9 CD40LG THPO
18 early congenital syphilis 9.9 CD40LG MYH9
19 aplastic anemia 9.9 ITGA2B MPL THPO
20 primary syphilis 9.9 CD40LG MYH9
21 thrombocytosis 9.9 MPL SELP THPO
22 granulomatous hepatitis 9.9 CD40LG ITGA2B
23 tertiary syphilis 9.9 CD40LG MYH9
24 cerebral arteriopathy, autosomal dominant, with subcortical infarcts and leukoencephalopathy, type 1 9.9
25 latent syphilis 9.9 CD40LG MYH9
26 heparin-induced thrombocytopenia 9.9 CD40LG SELP
27 congenital syphilis 9.8 CD40LG MYH9
28 polycythemia vera 9.8 MPL SELP THPO
29 asymptomatic neurosyphilis 9.8 CD40LG MYH9
30 ehrlichiosis 9.8 CD40LG SELP
31 legg-calve-perthes disease 9.8 CD40LG SELP
32 dengue disease 9.8 CD40LG THPO
33 megakaryocytic leukemia 9.8 ITGA2B THPO
34 thrombasthenia 9.8 ITGA2 ITGA2B SELP
35 syphilis 9.8 CD40LG MYH9
36 glanzmann thrombasthenia 9.8 ITGA2 ITGA2B SELP
37 idiopathic neutropenia 9.8 CD40LG THPO
38 tertiary neurosyphilis 9.7 CD40LG MYH9
39 gray platelet syndrome 9.7 CD40LG SELP
40 exanthema subitum 9.7 CD40LG ITGA2B THPO
41 immune system disease 9.7 CD40LG ITGA2B THPO
42 essential thrombocythemia 9.6 ITGA2B MPL SELP THPO
43 antiphospholipid syndrome 9.5 CD40LG SELP
44 bernard-soulier syndrome 9.5 ITGA2 ITGA2B MYH9 THPO
45 blood coagulation disease 9.4 CD40LG ITGA2B MPL THPO
46 purpura 9.4 CD40LG ITGA2B MPL THPO
47 myocardial infarction 9.1 CD40LG ITGA2 ITGA2B SELP
48 autoimmune disease of blood 8.9 CD40LG ITGA2 ITGA2B MPL THPO
49 blood platelet disease 8.6 CD40LG ITGA2B MPL MYH9 SELP THPO
50 primary thrombocytopenia 8.1 CD40LG ITGA2 ITGA2B MPL MYH9 SELP

Graphical network of the top 20 diseases related to Thrombocytopenia Due to Platelet Alloimmunization:



Diseases related to Thrombocytopenia Due to Platelet Alloimmunization

Symptoms & Phenotypes for Thrombocytopenia Due to Platelet Alloimmunization

MGI Mouse Phenotypes related to Thrombocytopenia Due to Platelet Alloimmunization:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 9.73 MYH9 SELP CD40LG ITGA2 ITGA2B MPL
2 hematopoietic system MP:0005397 9.7 SELP THPO CD40LG ITGA2 ITGA2B MPL
3 homeostasis/metabolism MP:0005376 9.5 MYH9 SELP THPO CD40LG ITGA2 ITGA2B
4 immune system MP:0005387 9.1 MYH9 SELP THPO CD40LG ITGA2B MPL

Drugs & Therapeutics for Thrombocytopenia Due to Platelet Alloimmunization

PubMedHealth treatment related to Thrombocytopenia Due to Platelet Alloimmunization: 59

Treatment for immune thrombocytopenia (ITP) is based on how much and how often you're bleeding and your platelet count.Adults who have mild ITP may not need any treatment, other than watching their symptoms and platelet counts. Adults who have ITP with very low platelet counts or bleeding problems often are treated.The acute (short-term) type of ITP that occurs in children often goes away within a few weeks or months. Children who have bleeding symptoms, other than merely bruising (purpura), usually are treated.Children who have mild ITP may not need treatment other than monitoring and followup to make sure their platelet counts return to normal.

Drugs for Thrombocytopenia Due to Platelet Alloimmunization (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 929)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3 50-02-2 5743
2
Amodiaquine Approved, Investigational Phase 4 86-42-0 2165
3
Artemether Approved Phase 4,Phase 3 71963-77-4 68911 119380
4
Artesunate Approved, Investigational Phase 4,Not Applicable 88495-63-0 5464098 6917864
5
Lumefantrine Approved Phase 4,Phase 3 82186-77-4 6437380
6
Mefloquine Approved, Investigational Phase 4 53230-10-7 4046
7
Alfentanil Approved, Illicit Phase 4 71195-58-9 51263
8
Methylprednisolone Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 83-43-2 6741
9
Prednisolone Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 50-24-8 5755
10
Estradiol Approved, Investigational, Vet_approved Phase 4,Phase 2 50-28-2 5757
11
Ethinyl Estradiol Approved Phase 4 57-63-6 5991
12
Moxifloxacin Approved, Investigational Phase 4 151096-09-2, 354812-41-2 152946
13
Norgestimate Approved, Investigational Phase 4 35189-28-7 6540478
14
Pyrimethamine Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 58-14-0 4993
15
Sulfadoxine Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 2447-57-6 17134
16
Pregabalin Approved, Illicit, Investigational Phase 4,Phase 3 148553-50-8 5486971
17
rituximab Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 174722-31-7 10201696
18
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 53-03-2 5865
19
Amoxicillin Approved, Vet_approved Phase 4,Phase 2,Phase 3 26787-78-0 33613 2171
20
Clarithromycin Approved Phase 4,Phase 2,Phase 3,Phase 1 81103-11-9 84029
21
Dexlansoprazole Approved, Investigational Phase 4 138530-94-6, 103577-45-3 9578005
22
Lansoprazole Approved, Investigational Phase 4 103577-45-3 3883
23
Zinc Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 7440-66-6 32051 23994
24
Everolimus Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 159351-69-6 6442177
25
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 22916-47-8 4189
26
Sirolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 53123-88-9 46835353 6436030 5284616
27
Adalimumab Approved Phase 4,Phase 3 331731-18-1 16219006
28
Vincristine Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 2068-78-2, 57-22-7 5978
29
Dinoprostone Approved Phase 4 363-24-6 5280360
30
Ketorolac Approved Phase 4 74103-06-3, 66635-83-4 3826
31
Nepafenac Approved, Investigational Phase 4 78281-72-8 151075
32
Ezetimibe Approved Phase 4 163222-33-1 150311
33
Simvastatin Approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 79902-63-9 54454
34
Citalopram Approved Phase 4,Phase 3,Phase 2 59729-33-8 2771
35
Lopinavir Approved Phase 4 192725-17-0 92727
36
Ritonavir Approved, Investigational Phase 4 155213-67-5 392622
37
Acetaminophen Approved Phase 4,Phase 3 103-90-2 1983
38
Pioglitazone Approved, Investigational Phase 4,Phase 2 111025-46-8 4829
39
Rosiglitazone Approved, Investigational Phase 4,Phase 1,Not Applicable 122320-73-4 77999
40
Heparin Approved, Investigational Phase 4,Phase 3,Not Applicable 9005-49-6 46507594 772
41
Acetylcysteine Approved, Investigational Phase 4 616-91-1 12035
42
Trimethoprim Approved, Vet_approved Phase 4 738-70-5 5578
43
Yohimbine Approved, Investigational, Vet_approved Phase 4 146-48-5 8969
44
Imipramine Approved Phase 4 50-49-7 3696
45
Desipramine Approved, Investigational Phase 4,Phase 2,Phase 1 50-47-5 2995
46
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 51-61-6, 62-31-7 681
47
Methamphetamine Approved, Illicit Phase 4,Phase 2,Phase 1,Not Applicable 537-46-2 10836
48
Labetalol Approved Phase 4 36894-69-6 3869
49
Nicardipine Approved, Investigational Phase 4,Phase 3 55985-32-5 4474
50
Iron Approved Phase 4,Phase 2,Not Applicable 7439-89-6 23925

Interventional clinical trials:

(show top 50) (show all 1440)

# Name Status NCT ID Phase Drugs
1 Caffeic Acid Combining High-dose Dexamethasone in Management of ITP Unknown status NCT02556814 Phase 4 Caffeic acid tablets;Dexamethasone;placebo
2 Efficacy and Safety of rHuTPO on Platelet Engraftment After Allo-HSCT Unknown status NCT01379391 Phase 4 Recombinant Human Thrombopoietin (rHTPO)
3 Effectiveness of Artemisinin Combination Regimens in Falciparum Malaria Unknown status NCT00902811 Phase 4 AM(FDC);AM(LT);AL;DP;AA(FDC)
4 Pain Evaluation During Follicle Aspiration: Comparison of Two Sedation Protocols Unknown status NCT00742807 Phase 4 Low dose of alfentanil hydrochloride;Normal dose of alfentanil hydrochloride
5 Comparison of a Nutritional Anti-Inflammatory Treatment to Steroids for Pediatric Crohn's Disease - the Molecular Basis Unknown status NCT00265772 Phase 4 MODULEN IBD (R) (specific Enteral Nutrition);prednisolon
6 Aqueous Absorption and Pharmacokinetics of Besivance Versus VIGAMOX in Patients Undergoing Phacoemulsification Unknown status NCT01296191 Phase 4 Moxifloxacin;besifloxacin
7 Graz Study on the Risk of Atrial Fibrillation Unknown status NCT01461434 Phase 4
8 tDCS as Add on Therapy for Treatment of Tobacco Dependence by Standardized Behaviour Therapy Unknown status NCT01729507 Phase 4
9 Intermittent Antimalaria Treatment With SP in African Children Unknown status NCT00168948 Phase 4 Sulfadoxin (12.5) Pyrimethamine (250 mg)
10 Efficacy and Safety of Amodiaquine and Amodiaquine-Artesunate Unknown status NCT00238017 Phase 4 amodiaquine-artesunate versus amodiaquine
11 Effects of Pregabalin on Mechanical Hyperalgesia Unknown status NCT00310583 Phase 4 Pregabalin
12 The Study of Different Dose Rituximab in the Treatment of ITP Completed NCT03258866 Phase 4 Rituximab;Rituximab
13 High-dose Dexamethasone Versus Conventional Dose Prednisone for Initial Treatment of Primary Immune Thrombocytopenia (ITP) Completed NCT01356511 Phase 4 Prednisone;Dexamethasone
14 Study on Bone Marrow Morphology in Adults Receiving Romiplostim for Treatment of Thrombocytopenia Associated With Immune Thrombocytopenia Purpura (ITP) Completed NCT00907478 Phase 4
15 Helicobacter Pylori Infection in Children With Chronic Idiopathic Thrombocytopenic Purpura Completed NCT00467571 Phase 4 lansoprazole, clarithromycin, amoxycillin
16 A Safety Study of Intravenous Immunoglobulin in Patients With Chronic Immune Thrombocytopenic Purpura (ITP) Completed NCT01390649 Phase 4
17 Platelet Function in Idiopathic Thrombocytopenic Purpura (ITP) Patients With Eltrombopag Completed NCT00888901 Phase 4 eltrombopag;corticosteroids (Aprednislon)
18 A Comparison of Prostaglandin E2 (PGE2) Inhibition of Acuvail(Ketorolac 0.45%), Xibrom (Bromfenac 0.09%)and Nevanac (Nepafenac)in Patients Undergoing Phacoemulsification Completed NCT01021761 Phase 4 Ketorolac Tromethamine;Bromfenac;nepafenac
19 A Comparison of Peak Aqueous Penetration of Acuvail (Ketorolac 0.45%), Xibrom (Bromfenac 0.09%), and Nevanac (Nepafenac 0.1%)in Patients Undergoing Phacoemulsification Completed NCT01001806 Phase 4 Ketorolac Tromethamine 0.45%;bromfenac 0.09%;nepafenac 0.1%
20 The PostprAndial eNdothelial Function After Combination of Ezetimibe and simvAstatin Study Completed NCT00817843 Phase 4 Simvastatin;Simvastatin/Ezetimibe
21 Comparison of Rotating vs. Fixed Platform of the COLUMBUS Knee Prosthesis Completed NCT00822640 Phase 4
22 Treatment of Depression in Adults Completed NCT00073697 Phase 4 Escitalopram
23 Raltegravir Kaletra Pharmacokinetics Completed NCT00564772 Phase 4 Raltegravir, lopinavir, ritonavir
24 Aqueous Concentrations and PGE2 Inhibition of Ketorolac 0.4% vs. Bromfenac 0.09% in Cataract Patients: Trough Drug Effects Completed NCT00469690 Phase 4 Acular, Xibrom
25 Paracetamol and Endothelial Function in Patients With Stable Coronary Artery Disease Completed NCT00534651 Phase 4 Paracetamol
26 A Comparison of Post Phacoemulsification Aqueous Flare in Patients Using Ketorolac 0.45% 2 Times Daily (BID) and Bromfenac 0.09% 2 Times Daily (BID) Completed NCT01023724 Phase 4 Ketorolac Tromethamine 0.45%;Bromfenac 0.09%
27 Effect of Thiazolidinedione Treatment Vascular Risk Markers Completed NCT00571506 Phase 4 Rosiglitazone;Pioglitazone
28 Mechanism of Fatty Acid-induced Impairment of Glucose-simulated Insulin Secretion - Effect of Buphenyl Completed NCT00533559 Phase 4 sodium phenylbutyrate;Placebo
29 Mechanism of Fatty Acid-Induced Impairment of Glucose-Stimulated Insulin Secretion Completed NCT00188773 Phase 4 N-acetylcysteine, intralipid, heparin
30 Moxifloxacin vs. Polytrim for Conjunctivitis Completed NCT00581542 Phase 4 moxifloxacin;polytrim
31 Mechanism of Growth Hormone Effects on Adipose Tissue Completed NCT00453557 Phase 4 rhGH
32 "TAKE TIME" Pioglitazone Reverses Defects in Mitochondrial Biogenesis in Patients With T2DM Completed NCT00402012 Phase 4 Pioglitazone
33 Aqueous Concentrations and PGE2 Inhibition of Ketorolac 0.4% vs. Bromfenac 0.09% in Cataract Patients Completed NCT00347503 Phase 4 ketorolac 0.4%, bromfenac 0.09%
34 Effects of Comorbid Personality Disorder on the Treatment of Bipolar I Disorder Completed NCT00178061 Phase 4
35 Oat Breakfast Satiety Study Completed NCT01372683 Phase 4
36 Bioequivalence Study Comparing Two Test Products With One Reference Product, All Containing 5 mg Yohimbine Completed NCT00975325 Phase 4 Yohimbine;Yohimbine
37 Miralax (PEG 3350) vs. Golytely as Bowel Preparation for Screening Colonoscopy Completed NCT01170754 Phase 4 PEG-3350 and Gatorade;Golytely 4 liters
38 Psychosocial Therapy Plus Maintenance Pharmacotherapy for Treating Bipolar Disorder Completed NCT00227968 Phase 4
39 Comparing Various Treatments for Achieving and Maintaining Remission of Depression Completed NCT00227955 Phase 4 Imipramine
40 Pharmacokinetic Study of Topically Applied Veregen 15% Compared With Oral Intake of Green Tea Beverage Completed NCT01082302 Phase 4 Polyphenon E (Veregen) 15% ointment
41 Xpert MTB/Rif, a New Tool for the Diagnosis of Pulmonary Tuberculosis in Two Municipalities in Brazil Completed NCT01363765 Phase 4
42 Is Omega-3 Fatty Acid Red Blood Cell (RBC) Saturation Product Dependent? Completed NCT01091714 Phase 4
43 Standard Open Surgery Versus Endovascular Repair of Abdominal Aortic Aneurysm (AAA) Completed NCT00094575 Phase 4
44 Effects of Ezetimibe on Postprandial Hyperlipidemia and Endothelial Function Completed NCT00189085 Phase 4 simvastatin and ezetimibe
45 Depression: The Search for Treatment-Relevant Phenotypes-Pilot Study Completed NCT00222820 Phase 4 escitalopram
46 Methamphetamine Abuse Treatment in Patients With AIDS - 1 Completed NCT00000321 Phase 4 Desipramine
47 Dry Age-Related Macular Degeneration (AMD) Treatment With Rheopheresis Trial Completed NCT00751361 Phase 4
48 Cryoplasty CLIMB-registry Completed NCT00459888 Phase 4
49 Evaluation of Intravenous Cardene(Nicardipine)and Labetalol Use in the Emergency Department Completed NCT00765648 Phase 4 nicardipine intravenous;Labetalol
50 Blood Glucose Self Monitoring and HbA1c Effects on Glucose Control Completed NCT00688363 Phase 4

Search NIH Clinical Center for Thrombocytopenia Due to Platelet Alloimmunization

Inferred drug relations via UMLS 69 / NDF-RT 47 :


Genetic Tests for Thrombocytopenia Due to Platelet Alloimmunization

Genetic tests related to Thrombocytopenia Due to Platelet Alloimmunization:

# Genetic test Affiliating Genes
1 Autoimmune Thrombocytopenia 28 FCGR2C

Anatomical Context for Thrombocytopenia Due to Platelet Alloimmunization

MalaCards organs/tissues related to Thrombocytopenia Due to Platelet Alloimmunization:

38
Bone Marrow, Bone, Testes, B Cells, T Cells, Liver, Spleen

Publications for Thrombocytopenia Due to Platelet Alloimmunization

Articles related to Thrombocytopenia Due to Platelet Alloimmunization:

(show top 50) (show all 339)
# Title Authors Year
1
Dynamic dosing of romiplostim in patients with immune thrombocytopenia purpura: Two case reports. ( 29357781 )
2018
2
Immune dysregulation in primary immune thrombocytopenia patients. ( 29409398 )
2018
3
Integrated mRNA and miRNA profiling revealed deregulation of cellular stress response in bone marrow mesenchymal stem cells derived from patients with immune thrombocytopenia. ( 29442265 )
2018
4
Subacute sclerosing panencephalitis and immune thrombocytopenia: More than a coincidence? ( 29407001 )
2018
5
Differential Expression of MiR-106b-5p and MiR-200c-3p in Newly Diagnosed Versus Chronic Primary Immune Thrombocytopenia Patients Based on Systematic Analysis. ( 29402802 )
2018
6
FcI^ receptor expression on splenic macrophages in adult immune thrombocytopenia. ( 28142207 )
2017
7
Immune Thrombocytopenia as a Consequence of Rocky Mountain Spotted Fever. ( 29279696 )
2017
8
Acquired Generalized Lipodystrophy Following Immune Thrombocytopenia. ( 28549922 )
2017
9
Infections in non-splenectomized persistent or chronic primary immune thrombocytopenia adults: risk factors and vaccination effect. ( 28078756 )
2017
10
Cytokine changes in response to TPO receptor agonist treatment in primary immune thrombocytopenia. ( 28142109 )
2017
11
From chronic immune thrombocytopenia to severe aplastic anemia: recent insights into the evolution of eltrombopag. ( 28473904 )
2017
12
Is oral all-trans retinoic acid plus danazol a refinement of second-line therapy for primary immune thrombocytopenia in adults? ( 28917656 )
2017
13
Refractory primary immune thrombocytopenia with subsequent del(5q) MDS: complete remission of both after lenalidomide. ( 28052942 )
2017
14
Successful treatment of bleeding with tranexamic acid in a series of 12 patients with immune thrombocytopenia. ( 28952160 )
2017
15
Immune thrombocytopenia of childhood responsive to tonsillectomy in the setting of chronic tonsillitis: A case report and literature review. ( 28648251 )
2017
16
Delayed Appearance of Cutaneous Lesions of Cutaneovisceral Angiomatosis (CAT) Leading to Misdiagnosis of Immune Thrombocytopenia. ( 28234740 )
2017
17
FC gamma receptor polymorphisms in patients with immune thrombocytopenia. ( 28942727 )
2017
18
Association Between TNF-I+ -308G/A Polymorphism and Risk of Immune Thrombocytopenia: A Meta-Analysis. ( 27960071 )
2017
19
Utility of the immature platelet fraction in pediatric immune thrombocytopenia: Differentiating from bone marrow failure and predicting bleeding risk. ( 28921855 )
2017
20
Oral all-trans retinoic acid plus danazol versus danazol as second-line treatment in adults with primary immune thrombocytopenia: a multicentre, randomised, open-label, phase 2 trial. ( 28917657 )
2017
21
Re: Severe Primary Autoimmune Thrombocytopenia (ITP) in Pregnancy: a national cohort study Primary immune thrombocytopenia management during pregnancy. A French study. ( 28940981 )
2017
22
Babesiosis-associated immune thrombocytopenia. ( 28217703 )
2017
23
Immune Thrombocytopenia Induced by Nivolumab in a Metastatic Non-Small Cell Lung Cancer Patient. ( 28950270 )
2017
24
Decreased function of Fas and variations of the perforin gene in adult patients with primary immune thrombocytopenia. ( 27391055 )
2017
25
Impaired function of Bone Marrow Mesenchymal Stem Cells from Immune Thrombocytopenia patients in inducing regulatory DC differentiation via the Notch-1/Jagged-1 signaling pathway. ( 28946811 )
2017
26
Rapid infusions of human normal immunoglobulin 50g/l are safe and well tolerated in immunodeficiencies and immune thrombocytopenia. ( 28073042 )
2017
27
Immune Thrombocytopenia and JAK2V617F Positive Essential Thrombocythemia: Literature Review and Case Report. ( 28808591 )
2017
28
Immune Thrombocytopenia in a Child with T Cell Lymphoblastic Lymphoma. ( 27668103 )
2016
29
Association of anticardiolipin, antiphosphatidylserine, anti-I^2 glycoprotein I, and antiphosphatidylcholine autoantibodies with canine immune thrombocytopenia. ( 27297331 )
2016
30
Participation of B-cell-activating factor receptors in the pathogenesis of immune thrombocytopenia. ( 26749059 )
2016
31
Interleukin-17-producing CD4+ T lymphocytes are increased in patients with primary immune thrombocytopenia. ( 26484642 )
2016
32
A Randomized Trial of Daily Prednisone versus Pulsed Dexamethasone in Treatment-NaA^ve Adult Patients with Immune Thrombocytopenia: EIS 2002 Study. ( 27189086 )
2016
33
Stromal cell-derived factor-1 rs2297630 polymorphism associated with platelet production and treatment response in Chinese patients with chronic immune thrombocytopenia. ( 26587874 )
2016
34
Increased RUNX1 expression in patients with immune thrombocytopenia. ( 27288310 )
2016
35
Spontaneous regression of adult T cell leukemia/lymphoma following development of immune thrombocytopenia. ( 26923458 )
2016
36
Association of TNF-I+ -308G>A and TNF-I^ +252A>G genes polymorphisms with primary immune thrombocytopenia: a North Indian study. ( 26761582 )
2016
37
Soluble Programmed Death 1 (PD-1) Is Decreased in Patients With Immune Thrombocytopenia (ITP): Potential Involvement of PD-1 Pathway in ITP Immunopathogenesis. ( 25510412 )
2016
38
Successful treatment of steroid-refractory immune thrombocytopenia with alemtuzumab. ( 28090498 )
2016
39
Primary versus secondary immune thrombocytopenia in adults; a comparative analysis of clinical and laboratory attributes in newly diagnosed patients in Southern Pakistan. ( 28064294 )
2016
40
Clinical course and prognostic factors of childhood immune thrombocytopenia: single center experience of 10 years. ( 27610182 )
2016
41
Decreased immunosuppressive actions of 1I+, 25-dihydroxyvitamin D3 in patients with immune thrombocytopenia. ( 27614264 )
2016
42
Elevated expression of NLRP3 in patients with immune thrombocytopenia. ( 26306997 )
2016
43
Thrombopoietin: a potential diagnostic indicator of immune thrombocytopenia in pregnancy. ( 26840092 )
2016
44
Immune thrombocytopenia associated with pleural and pericardial tuberculosis: case report. ( 27208577 )
2016
45
An increased expression profile of Th9/IL-9 correlated with Th17/IL-17 in patients with immune thrombocytopenia. ( 27662073 )
2016
46
The expression profile of toll-like receptor signaling molecules in CD19(+) B cells from patients with primary immune thrombocytopenia. ( 27210424 )
2016
47
Thromboembolism in adults with primary immune thrombocytopenia: a systematic literature review and meta-analysis. ( 27199203 )
2016
48
Immune thrombocytopenia purpura associated with multiple myeloma. ( 27178045 )
2016
49
Response of first line treatment with corticosteroids in a population-based cohort of adults with primary immune thrombocytopenia. ( 27633568 )
2016
50
Effects of the multidrug resistance-1 gene on drug resistance in primary immune thrombocytopenia. ( 27258931 )
2016

Variations for Thrombocytopenia Due to Platelet Alloimmunization

Expression for Thrombocytopenia Due to Platelet Alloimmunization

Search GEO for disease gene expression data for Thrombocytopenia Due to Platelet Alloimmunization.

Pathways for Thrombocytopenia Due to Platelet Alloimmunization

Pathways related to Thrombocytopenia Due to Platelet Alloimmunization according to KEGG:

36
# Name Kegg Source Accession
1 Phagosome hsa04145
2 Osteoclast differentiation hsa04380
3 Fc gamma R-mediated phagocytosis hsa04666

GO Terms for Thrombocytopenia Due to Platelet Alloimmunization

Cellular components related to Thrombocytopenia Due to Platelet Alloimmunization according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 plasma membrane GO:0005886 9.87 CD40LG FCGR2C ITGA2 ITGA2B MPL MYH9
2 cell surface GO:0009986 9.56 CD40LG ITGA2 ITGA2B MPL
3 focal adhesion GO:0005925 9.54 ITGA2 ITGA2B MYH9
4 external side of plasma membrane GO:0009897 9.26 CD40LG ITGA2 ITGA2B SELP
5 platelet alpha granule membrane GO:0031092 9.16 ITGA2B SELP
6 integrin complex GO:0008305 8.8 ITGA2 ITGA2B MYH9

Biological processes related to Thrombocytopenia Due to Platelet Alloimmunization according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cell proliferation GO:0008283 9.58 ITGA2 MPL THPO
2 cell adhesion GO:0007155 9.56 ITGA2 ITGA2B MYH9 SELP
3 platelet aggregation GO:0070527 9.37 ITGA2B MYH9
4 integrin-mediated signaling pathway GO:0007229 9.33 ITGA2 ITGA2B MYH9
5 leukocyte cell-cell adhesion GO:0007159 9.32 CD40LG SELP
6 thrombopoietin-mediated signaling pathway GO:0038163 8.96 MPL THPO
7 positive regulation of leukocyte migration GO:0002687 8.8 ITGA2 ITGA2B SELP

Sources for Thrombocytopenia Due to Platelet Alloimmunization

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....